New York, USA — Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight
For patients with advanced Dry Age-Related Macular Degeneration, also called geographic atrophy (GA), there is currently no FDA-approved therapy. There are, however, several treatments that are currently in clinical trials. Apl-2, Zimura, Oracea, and others are the drug molecules recently being investigated for the treatment of late-stage dry AMD. Strong Dry Age-related Macular Degeneration pipeline is anticipated to augment the market.
DelveInsight’s ‘Dry Age-related Macular Degeneration Pipeline Insight 2021′ report provides comprehensive global coverage of available, marketed, and pipeline Dry AMD therapies in various stages of clinical development, major pharmaceutical players working to advance the pipeline space and future growth potential of the Dry Age-related Macular Degeneration pipeline domain.
Key Takeaways from the Dry Age-related Macular Degeneration Pipeline Report
DelveInsight’s Dry Age-related Macular Degeneration Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ pipeline therapies.
Some of the key pharmaceutical players working to develop potential drug candidates to improve the Dry Age-related Macular Degeneration treatment landscape include Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix, and others.
Key Dry Age-related Macular Degeneration pipeline therapies in various stages of development include ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics, and others.
In July 2021, IVERIC bio announced the early completion of patient enrollment in GATHER2, the Company’s second pivotal clinical trial of Zimura® (avacincaptad pegol) in development for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
In June 2021, Ocular Therapeutix and Mosaic Biosciences entered into strategic discovery collaboration targeting the treatment of dry age-related macular degeneration. Under the terms of the agreement, Ocular Therapeutix has agreed to fund the research performed under the collaboration and retains all program inventions and associated intellectual property.
The US Food and Drug Administration (FDA) has granted Fast Track designation to Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
In January 2021 Gemini Therapeutics announced that GEM103, the company’s investigational treatment for dry AMD, had been granted Fast Track designation by the FDA.
In September 2020, the US FDA had granted Fast Track designation to GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
In December 2020, Janssen Pharmaceuticals announced the acquisition of rights to Hemera Biosciences, LLC’s investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD).
On January 13, 2022, ONL Therapeutics, announced that it has closed on its second tranche of the Company’s Series B financing. The total proceeds raised in the Series B was $46.9 million upon Achieving ONL1204 Development Milestones. The company is advancing ONL1204 into open-angle glaucoma and GA associated with dry AMD.
Request a sample and discover more about the report offerings @ Dry Age-related Macular Degeneration Pipeline Outlook
The Dry Age-related Macular Degeneration pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Dry Age-related Macular Degeneration products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Dry Age-related Macular Degeneration pipeline landscape.
Dry Age-related Macular Degeneration Overview
Age-related Macular Degeneration (AMD) is a degenerative disease of the ocular-posterior segment’s center (the macula lutea) that causes slow degeneration of central vision and severe disability in affected individuals. Clinically, AMD is classified using various methods. One such approach is to categorize the disease as early-stage to late-stage (advanced AMD). Advanced AMD is divided into two types: nonexudative or atrophic AMD (dry AMD) and exudative or neovascular AMD (wet AMD).
Find out more about the disease and recent developments @ Dry Age-related Macular Degeneration Pipeline Assessment
Dry Age-related Macular Degeneration Pipeline Drugs
Drug
Company
Phase
MoA
RoA
Zimura
IVERIC bio
Phase III
Complement C5 inhibitors
Intravitreous
ALK-001
Alkeus Pharmaceuticals
Phase III
Antioxidants
Oral
GT005
Gyroscope Therapeutics
Phase II
Complement factor I replacements; Gene transference
Subretinal
Risuteganib
Allegro Ophthalmics
Phase II
Integrin inhibitors
Intravitreous
GEM103
Gemini Therapeutics
Phase II
Complement factor H replacements
Intravitreous
CPCB-RPE1
Regenerative Patch Technologies
Phase I/II
Pluripotent stem cell therapies
Subretinal
RPESC RPE 4W
Luxa Biotechnology
Phase I/II
Cell replacements
Intraocular
Eyecyte RPE
Eyestem
Preclinical
Cell replacements
NA
OLX301A
OliX Pharmaceuticals
Preclinical
RNA interference
NA
EYS809
Eyevensys
Preclinical
Gene transference; Vascular endothelial growth factor A inhibitors
Intraocular
Dry Age-related Macular Degeneration Therapeutics Assessment
The Dry Age-related Macular Degeneration Pipeline report proffers an integral view of the Dry Age-related Macular Degeneration emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Scope of the Dry Age-related Macular Degeneration Pipeline Report
Coverage: Global
Therapeutic Assessment By Dry Age-related Macular Degeneration Product Type: Mono, Combination
Therapeutic Assessment By Dry Age-related Macular Degeneration Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration
Therapeutics Assessment By Dry Age-related Macular Degeneration Therapeutics Route of Administration: Oral, Intravenous, Inhalation, Subcutaneous
Therapeutics Assessment By Dry Age-related Macular Degeneration Therapies Molecule Type: Gene therapy, Stem cell therapy, Small molecules
Therapeutics Assessment By Dry Age-related Macular Degeneration Therapies Mechanism of Action: Complement C5 inhibitors, Complement factor I replacements; Gene transference, Integrin inhibitors, Complement factor H replacements, Pluripotent stem cell therapies, Cell replacements, RNA interference, Gene transference; Vascular endothelial growth factor A inhibitors, Fibroblast growth factor inhibitor, Mitochondrial permeability transition pore inhibitors, Cardiolipin modulators.
Key Dry Age-related Macular Degeneration Companies: Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix and others
Key Dry Age-related Macular Degeneration Pipeline Therapies: ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics and others
Dive deep into rich insights for emerging therapies and assessment, visit @ Dry Age-related Macular Degeneration Emerging Therapies
Table of Contents
1.
Introduction
2.
Executive Summary
3.
Dry Age-related Macular Degeneration: Overview
4.
Pipeline Therapeutics
5.
Late Stage Products (Phase III)
5.1.
Zimura: IVERIC bio
5.2.
ALK-001: Alkeus Pharmaceuticals
6.
Mid Stage Products (Phase II)
6.1.
GT005: Gyroscope Therapeutics
6.1.
GEM103: Gemini Therapeutics
7.
Early Stage Products (Phase I/II)
7.1.
CPCB-RPE1: Regenerative Patch Technologies
8.
Preclinical Stage Products
8.1.
OLX301A: OliX Pharmaceuticals
8.2.
Eyecyte RPE: Eyestem
9.
Therapeutic Assessment
10.
Inactive Products
11.
Dry Age-related Macular Degeneration Key Companies
12.
Dry Age-related Macular Degeneration Key Products
13.
Dry Age-related Macular Degeneration- Unmet Needs
14.
Dry Age-related Macular Degeneration- Market Drivers and Barriers
15.
Dry Age-related Macular Degeneration- Future Perspectives and Conclusion
16.
Dry Age-related Macular Degeneration Analyst Views
17.
Appendix
18.
About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight
